Abstract:Importance: Epilepsy is the most common neurological disorder of childhood. Identifying genetic diagnoses underlying epilepsy is critical to developing effective therapies and improving outcomes. Most children with non-acquired (unexplained) epilepsy remain genetically unsolved, and the utility of genome sequencing after nondiagnostic exome sequencing is unknown. Objective: To determine the diagnostic (primary) and clinical (secondary) utility of genome sequencing after nondiagnostic exome sequencing in individuals with unexplained pediatric epilepsy. Design: This cohort study performed genome sequencing and comprehensive analyses for 125 participants and available biological parents enrolled from August 2018 to May 2023, with data analysis through April 2024 and clinical return of diagnostic and likely diagnostic genetic findings. Clinical utility was evaluated. Setting: Pediatric referral center Participants: Participants with unexplained pediatric epilepsy and previous nondiagnostic exome sequencing; biological parents when available Exposure(s): Short-read genome sequencing and analysis Main Outcome(s) and Measure(s): Primary outcome measures were the diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding, and the unique diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding that required genome sequencing. The secondary outcome measure was clinical utility of genome sequencing, defined as impact on evaluation, treatment, or prognosis for the participant or their family. Results: 125 participants (58 [46%] female) were enrolled with median age at seizure onset 3 [IQR 1.25, 8] years, including 44 (35%) with developmental and epileptic encephalopathies. The diagnostic yield of genome sequencing was 7.2% (9/125), with diagnostic genetic findings in five cases and likely diagnostic genetic findings in four cases. Among the solved cases, 7/9 (78%) required genome sequencing for variant detection (small copy number variant, three noncoding variants, and three difficult to sequence small coding variants), for a unique diagnostic yield of genome sequencing of 5.6% (7/125). Clinical utility was documented for 4/9 solved cases (44%). Conclusions and Relevance: These findings suggest that genome sequencing can have diagnostic and clinical utility after nondiagnostic exome sequencing and should be considered for patients with unexplained pediatric epilepsy.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the diagnostic value and clinical application value of genome sequencing (GS) in pediatric patients with unexplained epilepsy for whom no cause has been diagnosed through exome sequencing (ES). Specifically, the researchers hope to understand whether performing genome sequencing can provide additional diagnostic information in these patients who have already undergone exome sequencing but failed to find a definite cause, and whether this diagnostic information is of practical help to the clinical management of patients. ### Research Background - **Epilepsy**: It is one of the most common neurological diseases in children, and about 1/26 of people will develop epilepsy at some stage in their lives. Identifying the genetic factors that cause epilepsy is crucial for developing effective treatment methods and improving prognosis. - **Importance of Genetic Diagnosis**: Most non - acquired (i.e., "unexplained") epilepsy cases remain genetically unexplained. Determining the genetic basis of these cases can end the long - term diagnostic process and may affect clinical management, including further examinations, treatment, and prognosis assessment. - **Existing Genetic Testing Methods**: Currently, commonly used genetic testing methods include chromosomal microarray (CMA), multi - gene panels, and exome sequencing (ES). Among them, exome sequencing is widely used because of its relatively high diagnostic rate (about 24%). - **Advantages of Genome Sequencing**: Compared with exome sequencing, genome sequencing can cover more gene regions, including non - coding regions outside the coding region, so it is possible to detect more types of genetic variations, such as single - nucleotide variants (SNVs), small insertions - deletions (indels), copy - number variants (CNVs), structural variants (SVs), short - tandem repeats (STRs), mobile - element insertions (MEIs), and mitochondrial variants. ### Research Objectives - **Primary Objective**: Determine the diagnostic value of genome sequencing in pediatric patients with unexplained epilepsy for whom no cause has been diagnosed by exome sequencing. - **Secondary Objective**: Evaluate the clinical application value of genome sequencing, that is, whether this diagnostic information has a practical impact on the clinical management of patients, such as affecting treatment decisions, providing prognosis information, or changing care plans. ### Research Design - **Study Cohort**: The study included 125 patients with unexplained pediatric epilepsy who had previously undergone exome sequencing but were not diagnosed, as well as their available biological parents. - **Genome Sequencing**: Genome sequencing was performed on these patients and their parents, and a comprehensive analysis was carried out. - **Primary Outcome Measures**: The diagnostic rate of genome sequencing, defined as the proportion of participants with diagnostic or potentially diagnostic genetic findings; and the unique diagnostic rate of genome sequencing, defined as the proportion of participants with diagnostic or potentially diagnostic genetic findings that can only be detected by genome sequencing. - **Secondary Outcome Measures**: The clinical application value of genome sequencing, defined as the situation where it has an impact on the assessment, treatment, or prognosis of participants or their families. ### Main Findings - **Diagnostic Rate**: Genome sequencing diagnosed 9 (7.2%) diagnostic or potentially diagnostic genetic findings in 125 participants, of which 5 were diagnostic genetic findings and 4 were potentially diagnostic genetic findings. - **Unique Diagnostic Rate**: Among the 9 diagnosed cases, 7 (78%) required genome sequencing to detect the variants, so the unique diagnostic rate of genome sequencing was 5.6%. - **Clinical Application Value**: Among the 9 diagnosed cases, 4 (44%) of the genetic findings had clinical application value, including affecting treatment decisions, providing prognosis information, etc. ### Conclusion The research results show that in pediatric patients with unexplained epilepsy for whom no cause has been diagnosed by exome sequencing, genome sequencing has significant diagnostic value and clinical application value. Therefore, genome sequencing should be regarded as the preferred detection method for such patients, or considered when exome sequencing fails to diagnose.

Utility of Genome Sequencing After Nondiagnostic Exome Sequencing in Unexplained Pediatric Epilepsy

Next Generation Sequencing in Children with Unexplained Epilepsy: A Retrospective Cohort Study.

Utility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes

High Diagnostic Yield and Clinical Utility of Next-Generation Sequencing in Children with Epilepsy and Neurodevelopmental Delays: A Retrospective Study

Clinical Utility of Exome Sequencing and Reinterpreting Genetic Test Results in Children and Adults With Epilepsy

Exome sequencing as first-tier genetic testing in infantile-onset pharmacoresistant epilepsy: diagnostic yield and treatment impact

Exome sequencing identifies molecular diagnosis in children with drug-resistant epilepsy

The role of genetic testing in adult patients with unexplained epilepsy

Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions

Next-generation sequencing in pediatric-onset epilepsies: Analysis with target panels and personalized therapeutic approach

Clinical Application of Targeted Next-Generation Sequencing Panels and Whole Exome Sequencing in Childhood Epilepsy

Rapid Whole Genome Sequencing: It Is Feasible! When Can We Implement It?

Clinical application of whole-exome sequencing analysis in childhood epilepsy

Pediatric Epilepsy Genetic Testing Results and Long-term Seizure Freedom

Next-generation sequencing testing in children with epilepsy reveals novel clinical, diagnostic and therapeutic implications

Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease

C.1 Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

A retrospective study of the yield of next‐generation sequencing in the diagnosis of developmental and epileptic encephalopathies and epileptic encephalopathies in 0–12 years aged children at a single tertiary care hospital in South India

Utility of next generation sequencing in paediatric neurological disorders: experience from South Africa

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: evidence from Canada